Blandt vaccinerede patienter, som udviklede PHN, reducerede ZOSTAVAX PHN- associerede (kroniske) smerter signifikant i forhold til placebo.
Among vaccinated individuals who developed PHN, ZOSTAVAX significantly reduced PHN-associated (chronic) pain compared with placebo.